Vise Technologies Inc. Purchases New Position in CVS Health Corporation $CVS

Key Points

• Vise Technologies acquired 58,892 CVS Health shares during the second quarter, valued at approximately $6.1 million. Institutional investors collectively own 80.66% of CVS shares.
• CVS reported quarterly EPS of $2.58, beating estimates of $1.87, while revenue rose 7.3% year over year to $106.1 billion. The company set fiscal 2026 EPS guidance at $7.90–$8.10.
• Analysts remain broadly positive, with 22 Buy ratings and two Holds, producing a “Moderate Buy” consensus and an average price target of $107.17. CVS also pays a quarterly dividend of $0.665 per share, yielding about 2.8% annually.

Vise Technologies Inc. acquired a new position in CVS Health Corporation (NYSE:CVS - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 58,892 shares of the pharmacy operator's stock, valued at approximately $6,092,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Elevation Wealth Partners LLC grew its position in CVS Health by 41.8% in the second quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator's stock worth $37,000 after acquiring an additional 105 shares in the last quarter. Apella Capital LLC raised its holdings in shares of CVS Health by 1.7% during the 2nd quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator's stock valued at $724,000 after purchasing an additional 117 shares in the last quarter. CYBER HORNET ETFs LLC lifted its stake in shares of CVS Health by 4.1% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator's stock valued at $259,000 after purchasing an additional 134 shares during the last quarter. Northwestern Mutual Investment Management Company LLC boosted its holdings in CVS Health by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator's stock worth $3,219,000 after purchasing an additional 136 shares in the last quarter. Finally, CoreCap Advisors LLC increased its position in CVS Health by 4.2% during the second quarter. CoreCap Advisors LLC now owns 3,481 shares of the pharmacy operator's stock worth $360,000 after buying an additional 139 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

CVS Health Stock Up 0.2%

CVS opened at $93.83 on Friday. The business has a 50 day moving average of $102.19 and a 200-day moving average of $88.83. The stock has a market capitalization of $120.01 billion, a price-to-earnings ratio of 24.82, a P/E/G ratio of 0.89 and a beta of 0.61. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same quarter in the previous year, the firm posted $1.81 earnings per share. CVS Health's revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date was Thursday, July 23rd. CVS Health's payout ratio is currently 70.37%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on CVS shares. UBS Group upped their price target on CVS Health from $122.00 to $126.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. DA Davidson upped their target price on CVS Health from $80.00 to $100.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of CVS Health from $88.00 to $92.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. Argus upped their price objective on shares of CVS Health from $104.00 to $114.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Wells Fargo & Company raised their target price on shares of CVS Health from $103.00 to $123.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, CVS Health has a consensus rating of "Moderate Buy" and a consensus price target of $107.17.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source